Relay Therapeutics vs Earendil Labs

About

Relay Therapeutics was founded in 2016 in Cambridge, Massachusetts, emerging from research at MIT and D.E. Shaw Research. The company is built around its Dynamo platform, which integrates computational protein motion modeling (molecular dynamics simulations) with structural biology and medicinal chemistry to design small-molecule drugs that exploit the dynamic conformational states of disease-relevant proteins—a dimension traditional structure-based drug design ignores.\n\nRelay's lead program, RLY-2608, is a first-in-class allosteric, mutant-selective PI3Kα inhibitor for advanced breast cancer patients with PI3KCA mutations. Unlike approved PI3Kα inhibitors that cause metabolic toxicity by inhibiting wild-type PI3Kα in normal tissues, RLY-2608 selectively targets the mutant form. The compound has shown early clinical promise including objective responses in patients who progressed on prior alpelisib, supporting a differentiated profile. Additional programs target FGFR2 and SHP2 in solid tumors.\n\nRelay has raised over $1.2 billion in equity financing and holds substantial cash reserves. The company is conducting multiple clinical trials and building a pipeline that validates its Dynamo-guided discovery approach. Though revenue-stage remains early, Relay represents a leading example of next-generation computational oncology companies seeking to turn protein dynamics insights into selective, differentiated medicines.